Клинічне та прогностичне значення ліпопротеїна (а)
DOI:
https://doi.org/10.37987/1997-9894.2015.1(186).222371Посилання
Anping Cai, Liwen Li, Ying Zhang et al. Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement // Disease Markers. – 2013. – Vol. 35, Issue 6. – P. 857–862.
Anping Cai, Liwen Li, Ying Zhang et al. Lipoprotein(a): a promising marker for residual cardiovascular risk assessment // Disease Markers. – 2013. – Vol. 35, Issue 5. – P. 551–559.
Dammerman M., Breslow J.L. Genetic basis of lipoprotein disorders // Circulation. – 1995. – Vol. 91. – P. 505–512.
Graham I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary // Eur. Heart J. – 2007. – Vol. 28. – P. 2375–2414.
Khan T.Z., Pottle A., Pennell D.J., Barbir M.S. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischemic heart disease and refractory angina // Global Cardiology Science and Practice. – 2014. – Vol. 3.
Malaguarnera M., Vacante M., Russo C. et al. Lipoprotein(a) in cardiovascular diseases // BioMed Research International. – 2013. – Article ID 650989, 9 pages. – http://dx.doi.org/10.1155/2013/650989.
Maranhao R.C., Carvalho P.O., Strunz C.C., Pileggi F. Lipoprotein (a): structure, pathophysiology and clinical implications // Arq. Bras. Cardiol. – 2014. – Vol. 103 (1). – P. 76–84.
Nordestgaard B.G., Chapman M.J., Ray K. et al. Lipoprotein(a) as a cardiovascular risk factor: current status // Eur. Heart J. – 2014. – Vol. 31 (23). – P. 2844–2853.
Safarova M.S., Ezhov M.V., Afanasieva O.I. et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography // Atheroscler. – 2013. – Vol. 14 (1). – P. 93–99.
